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Tapia,a Morena Pappalardo,b Xavier Barril, b Ruoyu Ma,c Cheng-Bin Zhang,c
Bin-Zhi Qian,c Miquel Sintes,d Ouldouz Ghashghaei, d Rodolfo Lavilla *d
and Marc Vendrell *a
Keratin 1 (KRT1) is overexpressed in squamous carcinomas and associated with aggressive pathologies in
breast cancer. Herein we report the design and preparation of the first Trp-based red fluorogenic amino
acid, which is synthetically accessible in a few steps and displays excellent photophysical properties, and
its application in a minimally-disruptive labelling strategy to prepare a new fluorogenic cyclopeptide for
imaging of KRT1+ cells in whole intact tumour tissues.Introduction
In recent years, optical molecular imaging has undergone
substantial development into the direct visualisation of cellular
features that are associated with disease processes.1–6 In this
context, the molecular complexity of the probes needed for
optimal biological performance requires modern synthetic
methods, oen beyond standard protocols.7 Our group and
others have demonstrated the value of peptide-based optical
probes as powerful tools to monitor cellular events in real
time.8–10 Suitable derivatisation of peptides with uorophores is
of paramount importance in chemical biology and optical
imaging. The most conventional labelling strategies involve the
formation of amide bonds between amino groups at the N-
terminal end or at the side chains of lysine (Lys) residues.
However, in some sequences this approach alters important
features of the native peptides (e.g., net charge, H-bonding
pattern) and can compromise the recognition and binding
affinity for their biomolecular targets.ty of Edinburgh, 47 Little France Crescent,
rell@ed.ac.uk
e Farma`cia, Universitat de Barcelona and
e Barcelona (IBUB), Av. Joan XXIII s/n,
iversity of Edinburgh, 47 Little France
of Pharmacy, University of Barcelona and
Barcelona (IBUB), Avda Joan XXIII 27-30,
b.edu
SI) available: Full synthetic procedures
l spectroscopic and biological data. See
of Chemistry 2019Alternatively, uorescent amino acids have emerged as
minimally-disruptive labelling strategy to construct optical
peptide-based probes.11–14 Our group has developed efficient
protocols to couple green-emitting BODIPY chromophores to
the C2 position of tryptophan (Trp) using Pd-catalysed C–H
activation processes.15–17 However, a major shortcoming of
existing uorogenic amino acids is their uorescence emission
in blue or green regions of the visible spectrum, which offer
limited sensitivity due to tissue autouorescence, particularly
during tissue imaging. Herein we report the rst red-emitting
Trp-based uorogenic amino acid and its optimal incorpora-
tion into a cyclic peptide to image the protein keratin 1 (KRT1),
which is overexpressed in aggressive breast cancer tumours.
Breast cancer is one of the most common malignancies in
women, accounting for 15% of total female cancer death in the
UK and making it the third most common cause of cancer
death. Early diagnosis is critical to achieve effective therapeutic
outcomes in patients and to enhance the survival rates.18
Tomographic andmammography imaging techniques, together
with magnetic resonance imaging, are regularly used in the
clinic to enhance the accuracy of diagnostic readouts, although
they are hampered by their limited spatial resolution and poor
specicity at the molecular level.19–21 To address these short-
comings, optical molecular imaging is being increasingly used
into routine clinical practice, and some translational probes to
study biological systems in situ have been reported.22,23
KRT1 is focally expressed in squamous carcinomas, which is
associated with a rare and aggressive pathology within breast
cancer.24,25 KRT1 is overexpressed in some breast cancer cell
lines (e.g., MDA-MB-231 and MDA-MB-435) whereas is only
present in low levels in non-cancerous cells (e.g., HUVEC).26,27
The group of Kaur identied by phage display the linear peptide
sequence p160, a 12-mer that can strongly bind KRT1 with KdChem. Sci.
Chemical Science Edge Article
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View Article Onlinevalues around 1 mM.26 In subsequent optimised generations, the
authors designed a proteolytically-stable cyclic derivative
including a D-Lys (Fig. 1).27 We envisaged that red uorogenic
analogues of the KRT1-binding sequence would enable imaging
of aggressive breast carcinomas, hence we designed a Trp(red-
BODIPY) building block (1, Fig. 1) for minimally-invasive
labelling of peptides with a uorophore emitting in the red
region. Furthermore, we compared the performance of this new
methodology to conventional labelling approaches and
prepared an analogue of peptide 2 by coupling the commercial
red uorescent BODIPY TR to the amino group on the side
chain of D-Lys.Scheme 1 Synthetic scheme for the preparation of the Fmoc-pro-
tected Trp(redBODIPY) (1) building block for SPPS.Results and discussion
Design and synthesis of Trp(redBODIPY)
We designed Trp(redBODIPY) (1) by extending the electronic
conjugation of Trp-BODIPY with a 2-methylthiophene moiety
directly coupled to the position 3 of the BODIPY scaffold. As in
other BODIPY dyes,28–30 we envisaged that this small (<100 Da)
chemical modication would signicantly red-shi the uo-
rescence emission wavelength while retaining most of the
molecular recognition properties derived from the Trp-based
amino acid. To this end, we envisaged a synthetic approach
for the amino acid 1 in which the key step would involve direct
arylation of Trp using Pd-catalysed C–H activation31 with an
appropriate haloaryl BODIPY derivative (Scheme 1).
We prepared the 3-iodophenyl-BODIPY precursor 3
through a convergent approach, suitable for the preparation
of non-symmetric BODIPY dyes, via regioselective synthesis of
the thiophenepyrrole derivative 4. Compound 4 was synthe-
sized by Suzuki–Miyaura coupling between the commercially
available N-Boc-pyrrole-2-boronic acid and 2-bromo-5-
methylthiophene, followed by basic deprotection. On the
other hand, the Friedel–Cras acylation between the m-iodo-
benzoic acid chloride and 2,4-dimethylpyrrole conveniently
afforded compound 6. The condensation of compounds 4 and
6 via POCl3 activation furnished 3-iodophenyl-BODIPY 3 aer
subsequent coordination with BF3$OEt2, although in low
yields (22%).32 Attempts to increase the recovery yields byFig. 1 Schematic illustration of the first red fluorescent Trp-based
amino acid and into incorporation into cyclic peptides to produce
fluorogenic probes for imaging of KRT1+ aggressive cancer cells.
Chem. Sci.altering the condensation reaction conditions, including the
presence of base or other acid catalysts, were unsuccessful.
Although literature precedents account for the feasibility of
this synthetic protocol,33–35 in this case we observed the
formation of the main byproduct 7 as a result of the compet-
itive dimerisation of the thiophenepyrrole 5 due to the acid-
catalysed interaction of an electron-rich pyrrole relatively
free of steric hindrance.36,37 Finally, we performed Pd-
catalysed C–H arylation of compound 3 with Fmoc-Trp-OH
to obtain the Fmoc-protected Trp(redBODIPY) (1), ready for
use in solid-phase peptide synthesis (SPPS). Spectral charac-
terisation of Trp(redBODIPY) (1) conrmed notable uoro-
genic behaviour with bathochromic shis in absorbance and
emission wavelengths (i.e., 60 nm longer when compared to
Trp-BODIPY) and uorescence spectrum covering the 570–610
nm range (Fig. S1–S4†).
Synthesis and characterisation of uorescent cyclopeptides
In view of the suitable optical properties of Trp(redBODIPY) (1),
we proceeded to the SPPS of uorescent derivatives of the KRT1-
binding cyclopeptide 2. Syntheses were performed on a 2-
chlorotrityl chloride polystyrene resin using standard depro-
tection and coupling SPPS conditions (i.e., DIC and Oxyma).38
Building blocks for polar amino acids were protected with H2-
labile groups (i.e., Tyr(Bzl), Glu(OBzl), D-Lys(Z)) that are
compatible with the BODIPY structure.39 In addition to the
unlabelled cyclopeptide 2, we prepared the Trp(redBODIPY)-
labelled counterpart (8) and the uorescent peptide including
the commercial dye BODIPY TR, with similar absorbance/
emission wavelengths to the amino acid 1 (Fig. S5†), whichThis journal is © The Royal Society of Chemistry 2019
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View Article Onlinewas coupled to the side chain of the D-Lys (9). All peptides were
obtained in a similar manner, combining an initial solid-phase
sequence elongation followed by head-to-tail peptide cyclisation
and nal removal of the protecting groups in solution
(Scheme 2).
Notably, we did not observe any signs decomposition of
Trp(redBODIPY) in any of the solid-phase procedures, high-
lighting the chemical stability and suitability of the amino acid
for peptide synthesis. The uorescent peptide 9 was readily
obtained by formation of an amide bond between the amino-
containing peptide 2 and the activated succinimidyl ester of
the commercially available dye BODIPY TR. The three peptides
were puried by preparative HPLC and isolated in purities >95%
(full characterisation data in ESI†).
Spectroscopic examination of the cyclopeptide 8 showed
that it retained the optical characteristics of Trp(redBODIPY)
(1) with uorescence emission around 600 nm, where tissue
autouorescence is typically low (Fig. 2). Peptide 8 also dis-
played remarkable uorogenic behaviour, with low emission
in aqueous media and up to 70-fold uorescent increase inScheme 2 Synthesis of KRT1-binding peptides. A combined solid- and s
(2), Trp(redBODIPY)-labelled (8) and BODIPY TR-labelled (9) peptides.
This journal is © The Royal Society of Chemistry 2019hydrophobic microenvironments (i.e., phosphatidylcholine
liposome suspensions) for enhanced signal-to-noise ratios
(Fig. 2). Given that proteases are abundant enzymes at
tumour sites, we also investigated the potential degradation
of the cyclopeptides 2 (unlabelled) and 8 [Trp(redBODIPY)-
labelled] when subjected to strong proteolytic environ-
ments. We incubated both peptides with a commercially
available protease cocktail at 37 C and recorded their
chemical stability by HPLC-MS over time. As expected for
cyclic structures, both peptides displayed good resistance to
proteolytic degradation, with the main products (2 and 8)
being the most abundant species even aer 24 h in the
proteolytic cocktail (Fig. 2 and S6†). We also observed that the
incorporation of the amino acid Trp(redBODIPY) into the
structure of the cyclopeptide 2 slightly augmented its resis-
tance to proteases, likely due to the inherent properties of
unnatural amino acids. Moreover, the incorporation of
Trp(redBODIPY) did not confer any cytotoxicity to the KRT1-
binding sequence as determined in cell viability assays with
HeLa cells (Fig. 2).olution-phase synthetic approach was employed to obtain unlabelled
Chem. Sci.
Fig. 2 (a) Absorbance and emission spectra of Trp(redBODIPY)-
labelled peptide 8 (10 mM) in EtOH. Normalised absorbance (solid line)
and fluorescence emission (dashed line, lexc.: 520 nm). (b) Fluorogenic
behaviour of cyclopeptide 8 (40 mM) in hydrophilic and hydrophobic
media (70-fold). Peptide 8 was incubated in PBS (black) or in phos-
phatidylcholine liposome suspensions (red, lexc.: 520 nm). (Inset)
Naked eye pictograms of both solutions under a hand-held UV lamp
using 365 nm excitation. (c) Stability of peptides in a protease cocktail
by HPLC monitoring. (d) Viability of HeLa cells after incubation with
different concentrations of peptide 8. Values are presented as means
 s.d. (n ¼ 4). Non-significant differences (p > 0.05) were observed
between the untreated control and any of the treatments.
Fig. 3 Representative conformations of unlabelled peptide 2 (green),
overlapped to: (a) the second most populated conformation of 2
(cyan); (b) themost representative conformation of peptide 8 (orange);
and (c) the most representative conformation of peptide 9 (grey). The
dashed circles highlight the hydrophobic core on each structure. (d)
Putative binding mode of peptide 2 (green) bound to KRT1 (grey
surface with cyan cartoon). Some contact residues are labelled for
reference. The pink spheres indicate binding hot spots identified with
MDmix. (e) Overlap with the experimental binding mode of KRT10
(grey cartoon and sticks), indicating the residues of the peptide 2
(green) and protein (white) that coincide. In this cartoon, KRT1 is
shown in cyan.
Chemical Science Edge Article
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View Article OnlineComputational analysis
At the computational level, we investigated the effects of BOD-
IPY labelling on the conformational preferences of the cyclo-
peptide 2 and on its binding to KRT1. For the rst aspect, we
used all-atom molecular dynamics simulations in explicit
aqueous solvation. The peptidic backbone of the unlabelled
peptide 2 was in rapid exchange among various conformations,
but the two most populated ones (i.e., representing 68% and
11% of the total population) were dened by the hydrophobic
collapse of the side chains Trp, Phe and norleucine (Nle)
(Fig. 3a). Trp(redBODIPY)-labelling preserved this hydrophobic
core, and the most abundant conformation of peptide 8 (64% of
the total population) clearly overlapped with the most abundant
conformation of 2 (Fig. 3b). In contrast, BODIPY TR-
conjugation on D-Lys disrupted the hydrophobic core and
altered the conformational preferences of the macrocycle. In
the most abundant conformation of peptide 9 (46% of total
population), the side chain of Nle was no longer involved in the
hydrophobic core. Instead, the aromatic rings of the BODIPY TR
uorophore stacked over the side chains of Phe and Trp,
creating an alternative hydrophobic core. The labelling of D-Lys
also increased the conformational diversity of peptide 9 (Table
S1†), which could negatively affect its binding to KRT1. In
contrast, the rigid Trp(redBODIPY) stabilised the original
conformation of the unlabelled peptide 2 and reduced its
accessible conformational space.Chem. Sci.In order to further understand the impact of BODIPY label-
ling on the ability of the cyclopeptides to bind KRT1, we
combined structural and sequence information of the protein
to generate a putative binding mode (ESI† for full details). The
condence on the docking predictions was supported by the
convergency of orthogonal data. The top-scoring docking solu-
tion for peptide 2 overlapped with multiple MDmix-predicted
hot spots40,41 and produced an outstanding structural align-
ment with KRT10,42 the natural partner of KRT1 (Fig. 3d and e).
The top-scoring solution of the Trp(redBODIPY)-labelled
peptide 8 coincided with that of peptide 2, whereas the lysine-
modied peptide 9 bound differently and showed
lower scores in the docking solutions (Fig. S12†). While this
computational analysis does not take into consideration
the complexity and potential heterogeneity of cellular systems
(e.g. quaternary structures of KRT1 with other keratins), our
results suggest that Trp(redBODIPY) labelling does not hinder
the natural binding properties of compound 2, in contrast to the
BODIPY TR conjugation to D-Lys.
Binding analysis and uorescence live-cell imaging of KRT1+
cells
We next examined the binding and imaging capabilities of the
uorescent cyclopeptides in human MDA-MB-231 cells as
a KRT1-positive highly aggressive and invasive epithelial, triple-This journal is © The Royal Society of Chemistry 2019
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View Article Onlinenegative breast cancer cell line.43 First, we performed ow
cytometric analysis to measure the relative binding affinity of
Trp(redBODIPY)-labelled peptide 8 (Fig. 4) for KRT1-
expressing cells. The Kd for peptide 8 was found to be
around 1 mM, in agreement with the values previously re-
ported for the unlabelled KRT1-binding sequences26,27 and in
line with our results from the computational analysis.
Notably, the analysis of peptide 9 in MDA-MB-231 cells indi-
cated around 5-fold weaker binding prole (Fig. S13†), which
indicates that the incorporation of a BODIPY-based amino
acid at the hydrophobic site of cyclopeptide 2 is less pertur-
bative than the classical derivatisation of a lysine residue with
the BODIPY TR dye. We also compared the uorogenic capa-
bilities and signal-to-noise ratios of both peptides 8 and 9 by
taking uorescence microscopy images of MDA-MB-231 cells
aer incubation with the two peptides with and without
washing. The uorogenic character of Trp(redBODIPY)
allowed us to acquire wash-free microscope images with good
signal-to-noise ratios, whereas peptide 9 only discriminated
subcellular structures aer washing (Fig. 4 and S14†).
Finally, we used peptide 8 for live-cell imaging in both
human MDA-MB-231 cells and HUVEC (Human Umbilical Vein
Endothelial) cells, which have differential expression levels of
KRT1. The red uorogenic peptide 8 brightly stained MDA-MB-Fig. 4 (a) Quantification of the signal-to-noise (S/N) ratios for
peptides 8 and 9 in MDA-MB-231 cells before and after washing
(fluorescencemicroscope images in Fig. S14†). Values are presented as
means  s.e.m. (n ¼ 3). (b) Flow cytometric analysis of MDA-MB-231
(KRT1+ cells) upon incubation with increasing concentrations of the
Trp(redBODIPY)-labelled peptide 8 (R2: 0.990). Values are presented
as means  s.d. (n ¼ 3). (c) Fluorescence microscope images of cells
expressing different levels of KRT1 (MDA-MB-231 as KRT1-positive,
HUVEC as KRT1-negative cells) upon incubation with the peptide 8
(red, 1 mM) and Hoechst 33342 for nuclear counterstaining (blue). Scale
bar: 10 mm.
This journal is © The Royal Society of Chemistry 2019231 cells whereas it showed minimal staining of HUVEC cells
under the same experimental conditions, indicating strong
dependence on the expression levels of KRT1 (Fig. 4).Multi-colour imaging of KRT1+ cells and tumour-associated
macrophages in aggressive tumours
Triple-negative breast cancer is an aggressive form of breast
cancer with limited therapeutic options, and where new
research tools for visualising and understanding its molecular
basis are needed in order to develop more effective treatments.
MDA-MB-231 cells are aggressive breast cancer cells, but there
are limited tools to study how they interact with immune cells in
the tumour microenvironment in whole intact tissues. Macro-
phages are the most abundant immune cells in tumours, and
there is evidence that subpopulations of tumour-associated
macrophages (TAMs) contribute to cancer progression and
metastatic seeding.44–48 Therefore, we decided to examine
whether the excellent properties of 8 as a red-emitting KRT1-
binding peptide would enable multi-colour imaging of aggres-
sive tumour cells in combination with TAM markers. First, we
induced the tumour formation in NCI nude mice by orthotopic
injection of MDA-MB-231 cells. Two weeks aer, tumours were
harvested for ex vivomulticolour uorescence staining. In order
to study the multicellular composition of aggressive tumour, we
incubated tumour tissue sections with peptide 8 (red), anti-Iba1
as a TAM marker (green) and DAPI for nuclear staining (blue).
As shown in Fig. 5, tumour tissues presented bright red
uorescence emission, indicating the presence of KRT1+
aggressive tumour cells. We also detected that some KRT1+ cellsFig. 5 Ex vivo tissue imaging of aggressive carcinomas under multi-
colour fluorescence confocal microscopy. Tumour-associated
macrophages were stained in green by anti-Iba1 and KRT1+ cells were
stained with peptide 8 (5 mM). DAPI was used for nuclear counter-
staining (blue). TAM–cancer cell interactions are identified with white
arrows. Scale bar: 10 mm.
Chem. Sci.
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View Article Onlinewere in proximity to green-uorescent Iba1 + TAMs, which
suggests their close interaction in aggressive carcinomas.
Whereas further studies will be necessary to characterise the
exact phenotype of TAMs in these tumours, we demonstrate the
utility of the peptide 8 in uorescence imaging studies aimed at
understanding dynamic interactions between immune cells and
cancer cells in tumour tissues in situ.
Conclusions
In summary, we describe the preparation of Trp(redBODIPY) as
the rst red-emitting Trp-based amino acid by Pd-catalysed
coupling to a thiophene-appended BODIPY uorophore.
Trp(redBODIPY) is compatible with conventional SPPS proto-
cols and it was used to synthesize a minimally-disrupted KRT1-
binding peptide with red uorogenic properties. Notably, our
computational and experimental data indicates that the incor-
poration of Trp(redBODIPY) within KRT1-binding sequences is
more favourable than the conventional lysine derivatisation
with BODIPY TR, in terms of binding mode, protein affinity
and signal-to-noise ratios. Finally, we used the Trp(redBODIPY)-
labelled cyclopeptide 8 for live-cell and ex vivo imaging of
KRT1+ cancer cells and to study their interactions with tumour-
associated macrophages in aggressive carcinomas.
Ethical statement
This study was performed in strict accordance with the guide-
lines on the United Kingdom Animals Act 1986 for the care and
use of laboratory animals. The work was approved by the Home
Office (Animals in Science Regulation Unit) and performed
under the local rules and guidance of the Animal Welfare and
Ethical Review Body at The University of Edinburgh (Edinburgh,
UK), which is a designated User and Supplying Establishment
under ASPA (1986) with PEL number 60/6205.
Conflicts of interest
The authors declare no conicts of interest.
Acknowledgements
R. S. F acknowledges a MSCA Individual Fellowship (659046). N.
D. B. acknowledges funding from OPTIMA (EP/L016559/
1). L. M. T. acknowledges the support of Fundacion Antonio
Martin Escudero (FAME) in the form of a post-doctoral fellow-
ship. B. Q. acknowledges funds from a CRUK Career Develop-
ment Fellowship (C49791/A17367) and an ERC Starting Grant
(716379). R. L. acknowledges support from the Ministerio de
Economı´a y Competitividad-Spain (CTQ2015-67870-P, ERA-NET
PCIN-2015-224), Generalitat de Catalunya (2017 SGR
1439). M. V. acknowledges funds from an ERC Consolidator
Grant (771443) andWellcome Trust iTPA (PIII-006). The authors
acknowledge support from EP/M507258/1 (Equipment grant)
and thank the technical support from the Flow Cytometry and
the Confocal Advanced Light Microscopy units at the University
of Edinburgh.Chem. Sci.Notes and references
1 M. Vendrell, D. Zhai, J. C. Er and Y. T. Chang, Chem. Rev.,
2012, 112, 4391–4420.
2 L. Chen, S. Xu, W. Li, T. B. Ren, L. Yuan, S. S. Zhang and
X. Zhang, Chem. Sci., 2019, 10, 9351–9357.
3 H. Li, Y. Li, O. Yao, J. Fan, W. Sun, S. Long, K. Shao, J. Du,
J. Wang and X. Peng, Chem. Sci., 2019, 10, 1619–1625.
4 M. Li, S. Long, Y. Kang, L. Guo, J. Wang, J. Fan, J. Du and
X. Peng, J. Am. Chem. Soc., 2018, 140, 15820–15826.
5 N. Kielland, M. Vendrell, R. Lavilla and Y. T. Chang, Chem.
Commun., 2011, 48, 7401–7403.
6 S. J. Park, H. C. Yeo, N. Y. Kang, H. Kim, J. Lin, H. H. Ha,
M. Vendrell, J. S. Lee, Y. Chandran, D. Y. Lee, S. W. Yun
and Y. T. Chang, Stem Cell Res., 2014, 12, 730–741.
7 F. de Moliner, N. Kielland, R. Lavilla and M. Vendrell, Angew.
Chem., Int. Ed., 2017, 56, 3758–3769.
8 C. Zhao, L. Mendive-Tapia and M. Vendrell, Arch. Biochem.
Biophys., 2019, 661, 187–195.
9 D. Wu, H. C. Daly, M. Grossi, E. Conroy, B. Li,
W. M. Gallagher, R. Elmes and D. F. O'Shea, Chem. Sci.,
2019, 10, 6944–6956.
10 A. H. Harkiss and A. Sutherland, Org. Biomol. Chem., 2016,
14, 8911–8921.
11 P. Cheruku, J. H. Huang, H. J. Yen, R. S. Iyer, K. D. Rector,
J. S. Martinez and H. L. Wang, Chem. Sci., 2015, 6, 1150–
1158.
12 J. Ge, L. Li and S. Q. Yao, Chem. Commun., 2010, 47, 10939–
10941.
13 A. H. Harkiss, J. D. Bell, A. Knuhtsen, A. G. Jamieson and
A. Sutherland, J. Org. Chem., 2019, 84, 2879–2890.
14 A. V. Strizhak, V. Y. Postupalenko, V. V. Shvadchak,
N. Morellet, E. Guittet, V. G. Pivovarenko,
A. S. Klymchenko and Y. Me´ly, Bioconjugate Chem., 2012,
23, 2434–2443.
15 L. Mendive-Tapia, C. Zhao, A. R. Akram, S. Preciado,
F. Albericio, M. Lee, A. Serrels, N. Kielland, N. D. Read,
R. Lavilla and M. Vendrell, Nat. Commun., 2016, 7, 10940.
16 L. Mendive-Tapia, R. Subiros-Funosas, C. Zhao, F. Albericio,
N. D. Read, R. Lavilla and M. Vendrell, Nat. Protoc., 2017, 12,
1588–1619.
17 R. Subiros-Funosas, L. Mendive-Tapia, J. Sot, J. D. Pound,
N. D. Barth, Y. Varela, F. M. Gon˜i, M. Paterson,
C. D. Gregory, F. Albericio, I. Dranseld, R. Lavilla and
M. Vendrell, Chem. Commun., 2017, 53, 945–948.
18 B. Weigelt, J. L. Peterse and L. J. Van't Veer, Nat. Rev. Cancer,
2005, 5, 591–602.
19 A. Poellinger, J. Biophotonics, 2012, 5, 815–826.
20 J. S. Drukteinis, B. P. Mooney, C. I. Flowers and
R. A. Gatenby, Am. J. Med., 2013, 126, 472–479.
21 B. B. Koolen, W. V. Vogel, M. J. Vrancken Peeters, C. E. Loo,
E. J. T. Rutgers and R. A. Valde´s Olmos, J. Oncol., 2012, 2012,
438647.
22 Q. T. Nguyen, E. S. Olson, T. A. Aguilera, T. Jiang,
M. Scadeng, L. G. Ellies and R. Y. Tsien, Proc. Natl. Acad.
Sci. U. S. A., 2010, 107, 4317–4322.This journal is © The Royal Society of Chemistry 2019
Edge Article Chemical Science
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
8 
D
ec
em
be
r 2
01
9.
 D
ow
nl
oa
de
d 
on
 1
/1
4/
20
20
 2
:2
9:
53
 P
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online23 T. Nagaya, Y. A. Nakamura, P. L. Choyke and H. Kobayashi,
Front. Oncol., 2017, 7, 314.
24 V. Karantza, Oncogene, 2011, 30, 127–138.
25 R. Moll, M. Divo and L. Langbein, Histochem. Cell Biol., 2008,
129, 705–733.
26 R. Soudy, H. Etayash, K. Bahadorani, A. Lavasanifar and
K. Kaur, Mol. Pharm., 2017, 14, 593–604.
27 Y. Raghuwanshi, H. Etayash, R. Soudy, I. Paiva,
A. Lavasanifar and K. Kaur, J. Med. Chem., 2017, 60, 4893–
4903.
28 L. H. Thoresen, H. Kim, M. B. Welch, A. Burghart and
K. Burgess, Synlett, 1998, 1276–1278.
29 T. Kowada, H. Maeda and K. Kikuchi, Chem. Soc. Rev., 2015,
44, 4953–4972.
30 A. Fernandez, M. Vermeren, D. Humphries, R. Subiros-
Funosas, N. Barth, L. Campana, A. MacKinnon, Y. Feng
and M. Vendrell, ACS Cent. Sci., 2017, 3, 995–1005.
31 S. Preciado, L. Mendive-Tapia, F. Albericio and R. Lavilla, J.
Org. Chem., 2013, 78, 8129–8135.
32 The alternative condensation from the corresponding
alcohol and the pyrrole derivatives, followed by DDQ
oxidation and BF3 coordination was unsuccessful. For
a recent example of this approach, see: J. Y. Kim, S. Sahu,
Y. H. Yau, X. Wang, S. G. Shochat, P. H. Nielsen,
M. S. Dueholm, D. E. Otzen, J. Lee, M. M. S. Delos Santos,
J. K. Hoong Yam, N. Y. Kang, S. J. Park, H. Kwon,
T. Seviour, L. Yang, M. Givskov and Y. T. Chang, J. Am.
Chem. Soc., 2016, 138, 402–407.
33 V. Leen, E. Braeken, K. Luckermans, C. Jackers, M. Van der
Auweraer, N. Boens and W. Dehaen, Chem. Commun., 2009,
4515–4517.
34 H. Wu, B. T. Cisneros, C. M. Cole and N. K. Devaraj, J. Am.
Chem. Soc., 2014, 136, 17942–17945.
35 R. I. Lerrick, T. P. L. Winstanley, K. Haggerty, C. Wills,
W. Clegg, R. W. Harrington, P. Bultinck, W. Herrebout,This journal is © The Royal Society of Chemistry 2019A. C. Bennistona and M. J. Hall, Chem. Commun., 2014, 50,
4714–4716.
36 The pattern of the 2:30 dimerization is uncommon in related
processes but has a logical electronic interpretation:
electrophilic protonation in the a-position and subsequent
b-attack of the other pyrrole from its a-position. For the
standard trimerization of pyrrole under acid catalysis, see:
Y. Zhao, R. L. Beddoes and J. A. Joule, J. Chem. Res., 1997,
42–43.
37 For the analogous and better described indole dimerization,
see: T. Guo, S. L. Han, Y. C. Liu, Y. Liu and H. M. Liu,
Tetrahedron Lett., 2016, 57, 1097–1099 and references cited
therein.
38 R. Subiro´s-Funosas, R. Prohens, R. Barbas, A. El-Faham and
F. Albericio, Chem.–Eur. J., 2009, 15, 9394–9403.
39 M. Vendrell, G. G. Krishna, K. K. Ghosh, D. Zhai, J.-S. Lee,
Q. Zhu, Y. H. Yau, S. G. Shochat, H. Kim, J. Chung and
Y.-T. Chang, Chem. Commun., 2011, 47, 8424–8426.
40 J. Seco, F. J. Luque and X. Barril, J. Med. Chem., 2009, 52,
2363–2371.
41 D. Alvarez-Garcia and X. Barril, J. Med. Chem., 2014, 57,
8530–8539.
42 C. G. Bunick and L. M. Milstone, J. Invest. Dermatol., 2017,
137, 142–150.
43 G. Bianchini, J. M. Balko, I. A. Mayer and M. E. Sanders, Nat.
Rev. Clin. Oncol., 2016, 13, 674–690.
44 P. D. Bos, D. X. Nguyen and J. Massague´, Curr. Opin.
Pharmacol., 2010, 10, 571–577.
45 B. Z. Qian and J. W. Pollard, Cell, 2010, 141, 39–51.
46 B. Z. Qian, J. Li, H. Zhang, T. Kitamura, J. Zhang,
L. R. Campion, E. A. Kaiser, L. A. Snyder and J. W. Pollard,
Nature, 2011, 475, 222–225.
47 A. Fernandez, E. Thompson, J. W. Pollard, T. Kitamura and
M. Vendrell, Angew. Chem., Int. Ed., 2019, 58, 16894–16898.
48 T. Kitamura, B. Z. Qian and J. W. Pollard, Nat. Rev. Immunol.,
2015, 15, 73–86.Chem. Sci.
